Acne 

Actinic Keratosis 

Aesthetics

Alopecia

Biologic Treatments for Moderate to Severe Atopic Dermatitis 

Atopic Dermatitis 

Buy-and-Bill

COVID-19

Case-Based Roundtable

Chronic Hand Eczema

Chronic Spontaneous Urticaria 

Drug Watch

Eczema

General Dermatology 

Hidradenitis Suppurativa

Melasma

NP and PA

Pediatric Dermatology

Pigmentary Disorders 

Practice Management 

Precision Medicine and Biologics

Prurigo Nodularis

Emerging Therapies Plaque Psoriasis

Treatments for Plaque Psoriasis 

Psoriasis 

Psoriatic Arthritis 

Rare Disease

Rosacea 

Skin Cancer (Nonmelanoma)

Skin Cancer

Vitiligo

Wound Care

News

Media

Around the Practice

Between The Lines

Case-Based Peer Perspective

Clinical Case Collective

DermView

Expert Perspectives

Fellows Face Off

Frontline Forum

Medical World News

Patient Perspectives

Podcasts

Readout360

Recognize and Refer

Conferences

Conference Coverage

Conference Listing

Events

Publication

Dermatology Times

CME/CE

Resources

DermIQ

Interactive Tools

Job Board

Partner Perspectives

Perspectives in Dermatology

Polls

Spot Test

Editorial Advisory Board

Partners

Subscribe

Maddi Hebebrand is an associate editor of 

and joined the MJH Life Sciences team in May 2024. She attended Baldwin Wallace University, studying Media Production and Film, and received her Masters in Digital Media from Ohio University. When she's not writing, Maddi loves to read, attend concerts and spend time with her family. 

Articles

This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.

The Rx Recap: August 17-22

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Daily Derm Times: August 22, 2025

Omar Noor leads a dynamic discussion on personalized psoriasis therapy, addressing patient challenges and innovative treatment options.

Tailoring Psoriasis Care to Patients, Not Just Protocols

Clinicians explore innovative strategies for managing atopic dermatitis, emphasizing personalized care and the use of non-steroidal treatments for improved patient outcomes.

Experts Compare Real-World Use of Emerging AD Treatments

Dermatology Times connects dermatology professionals with key skin disorder coverage, therapeutic strategies, clinical trial updates, and expert insights.

About

Advertise

Contact Us

Do Not Sell My Information

Terms and Conditions

Privacy Policy

Dermatology Times - Dermatology News and Clinical Insights

Facebook

Linkedin

Topics

Acne

Pigmentary Disorders

Practice Management

Psoriasis

Psoriatic Arthritis

Rosacea

1rem

Authors

Jerome Okudo, MD, MPH, is a researcher in the Department of Public Health at the University of Texas Health Science Center at Houston.

A case report presents a unique case of Bowen's disease affecting the lower
extremities in a 75-year-old woman, which was initially misdiagnosed as a fungal infection. 

Bowen’s Disease on Lower Extremities: A Rare Case Report

Final Thoughts: The Importance of Comparative Studies in AD

Panelists offer concluding insights and emphasize the critical role of comparative studies in advancing atopic dermatitis treatment strategies.

clinical

Video Series

 approximately 2% of people worldwide will experience hair loss due to alopecia areata in their lifetime. 

When taking this statistic into account, approximately 160 million people globally have had, currently have, or will have alopecia areata, including approximately 6.7 million in the US. 

At this moment in time, it can be approximated that 700,000 people in the US, both children and adults, currently have some form of alopecia areata.

Alopecia areata - National Alopecia Areata Foundation. NAAF. June 23, 2023. Accessed August 11, 2023. 

Alopecia areata affects approximately 2% of the global population, translating to around 160 million individuals worldwide. In the United States, about 6.7 million people have experienced or will experience this condition, with an estimated 700,000 currently affected. This autoimmune disorder impacts both children and adults, leading to varying degrees of hair loss. The data underscores the prevalence of alopecia areata and highlights the need for continued research and awareness to better understand and manage this condition.

This Hair Loss Awareness Month, test your knowledge of hair loss conditions. Click here to answer this week's poll.

POLL: What Percentage of People Worldwide Will Experience Alopecia in Their Lifetime?

To stay up-to-date with the latest dermatology news, sign up to receive our 

Recognizing the Hidden Burdens of Pediatric Psoriasis

Pediatric psoriasis poses unique treatment challenges, highlighting the importance of early intervention and awareness of comorbidities in young patients.

FDA Grants Orphan Drug Designation to Dusquetide for Behçet’s Disease

Orphan designation provides Soligenix with potential regulatory, financial, and exclusivity benefits as it develops SGX945.

How Dr. Rossi DERM MD Skin Care Combats Inflammatory Aging

Discover Anthony Rossi, MD, FAAD, FACMS's innovative skin care line targeting inflammatory aging with clinical science, clean formulations, and effective anti-aging solutions.

POLL: What Aesthetic Trends Are You Seeing in Gen Z and Millennial Patients?

Answer today's poll and explore the evolving aesthetic trends among Millennials and Gen Z, focusing on their unique preferences for skin care, fillers, and Botox treatments.

Vitiligo Management in Practice: Expert Case Reviews

Ted Lain, MD, MBA, moderated a Case-Based Roundtable event to discuss diverse case presentations of vitiligo and how to build a treatment regimen.

From Scalp to Skin: Modernizing Psoriasis Treatment With Versatile Topical Solutions

Explore the latest advancements in psoriasis treatment with innovative topical therapies, enhancing patient outcomes and simplifying management for diverse skin types.

Jean Tang, MD, PhD, Reflects on FDA Approval of pz-cel for EB

Jean Tang, MD, PhD, professor of dermatology at Stanford University and general dermatologist at Stanford Medicine Children’s Health, highlighted how the therapy harnesses a patient’s own skin cells and corrects the COL7A1 mutation ex vivo.

Anthony Rossi, MD, FAAD, FACMS, Discusses Science, Simplicity, and the Skin

Dr. Rossi DERM MD blends dermatologic science with K-beauty aesthetics for effective, evidence-based solutions.

Leaving Home Sparks New Challenges in Atopic Dermatitis Care

Expanded prescribing rights for pharmacists could ease treatment delays and improve access for AD patients.

Navigating a New Era of AD Treatment Options

Explore expert insights from Adam Friedman, MD, FAAD, on emerging topical treatments for atopic dermatitis, featuring real-world cases and practical strategies for improving care and access.

How New Topical Therapies Are Transforming Atopic Dermatitis Care

At the Elevate-Derm Summer 2025 meeting, Walter Liszewksi, MD, discussed how new topical therapies, particularly JAK inhibitors, are transforming AD care with rapid itch relief, effectiveness in complex cases, and patient-friendly formulations for sensitive areas.

This review of the latest dermatologic studies includes a case study of coexisting alopecia and BP treatment, hypochlorous acid for epidermolysis bullosa wounds, DMG-Na and caffeine for hair loss, and more.

Karen McGuire, PhD, on Advancing TAMES-02 Trial for EB Simplex

Karen McGuire, PhD, discusses TAMES-02, a clinical trial evaluating TolaSure for Epidermolysis Bullosa Simplex.

Evolus Submits Evolysse Sculpt for FDA Approval, Expanding HA Dermal Filler Portfolio

Evolus advances facial aesthetics with Evolysse Sculpt, a new hyaluronic acid gel targeting mid-face volume loss, pending FDA approval.

Unpacking the Role of Gene Expression Profiling in Melanoma

At DERM 2025, David Cotter, MD, PhD, shared how GEP testing revolutionizes skin cancer management and enhances patient care at the forefront of dermatology innovation.

Patient Trust Hinges on Clinician Oversight in AI and Telehealth

Oversight and endorsement from trusted clinicians were consistent patient requirements for integrating both AI and telemedicine.

Henry W. Lim, MD, on World Skin Health Day's Global Push for Prioritizing Dermatology

World Skin Health Day unites global dermatology leaders to enhance skin health awareness, access, and equity in underserved communities worldwide.

Highlighting Individualized Strategies in Vitiligo Care Across Diverse Cases

 Case-Based Roundtable event, Pearl Grimes, MD, led discussions on diverse vitiligo cases spanning adult, pediatric, and rapidly progressive disease, emphasizing individualized treatment strategies.

Targeting Shared Pathways: Tofacitinib for Co-Occurring Vitiligo and Discoid Lupus Erythematosus

Tofacitinib shows promise in treating vitiligo secondary to discoid lupus erythematosus, achieving significant repigmentation and lesion resolution.

Septerna Begins First-in-Human Trial of SEP-631 for CSU

The randomized, placebo-controlled trial will evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics in up to 150 healthy volunteers.

Delivering Skin Health to Isolated Islands with the Philippine Dermatological Society and ILDS

In celebration of World Skin Health Day, Jasmin Jamora, MD, and her team at PDS enhance skin health access in remote areas through outreach clinics and education.

Bridge to Relief: Art Garfunkel's Psoriatic Journey

Art Garfunkel raises awareness about psoriasis, sharing his journey and the impact of tildrakizumab treatment in a campaign for support and hope.

Microfocused Ultrasound With Visualization for Arm and Abdomen Skin Quality: Global Perspective Beyond the Face

Microfocused ultrasound enhances skin quality beyond the face, offering noninvasive solutions for arms and abdomen with high patient satisfaction.

A Head-to-Head Analysis of Conjunctivitis in Atopic Dermatitis Therapies

James Song, MD, FAAD, reveals insights on abrocitinib's safety in atopic dermatitis, highlighting lower conjunctivitis rates compared to dupilumab at DERM 2025.

Derm Dispatch: Mentorship as the Future of Dermatology

Strong mentorship provides resilience for young clinicians navigating evolving challenges in practice.

A case report presents a unique case of Bowen's disease affecting the lower extremities in a 75-year-old woman, which was initially misdiagnosed as a fungal infection.

Addressing BSA Limitations and Evolving Patient Needs in Atopic Dermatitis

Walter Liszewski, MD, shares expert strategies for managing body surface area limitations in AD treatment using non-steroidal topicals, and explored key unmet needs in the current therapeutic landscape.

Key Opinion Leaders Share Top Clinical Insights for Physician Associates

Clinicians at the SDPA Annual Summer Dermatology Conference explore innovative treatments, diagnostic strategies, and patient-centered care in dermatology.

World Skin Health Day: Solving Dermatologic Disparity and Leading Educational Outreach in Remote Communities

Vinna Crisostomo, MD, leads vital skin health initiatives in Palawan, addressing access and education challenges for underserved communities on World Skin Health Day.

April Martinez-Dulay, MSN, APRN, FNP-BC, Shares Clinical Pearls on Dermatitis and Lymphoma

April Martinez-Dulay, MSN, APRN, FNP-BC, shares insights on diagnosing and treating types of dermatitis at DERM 2025, emphasizing innovative approaches and patient care strategies.

Mentorship Program Targets Real-World Representation

Mentors and mentees include specialists in complex medical dermatology, pediatric dermatology, and procedural dermatology to diversify trial opportunities.

Recent advancements in dermatology highlight significant progress in psoriasis treatment, pediatric dermatology, and autoimmune disorder therapies. Notable developments include Nektar's Rezpegaldesleukin for autoimmune conditions, guselkumab's long-term benefits for plaque psoriasis, and pembrolizumab's approval for head and neck cancer in Canada. The importance of addressing moderate psoriasis seriously and recognizing the burden of low BSA psoriasis is emphasized. Additionally, the impact of vitiligo on life choices and the need for accurate health information on platforms like TikTok are underscored.

In case you missed it, this week we had news about Art Garfunkel's decades-long journey with psoriasis, the first in-human trial of SEP-631 for CSU, the impact of World Skin Health Day, and more.

The Weekly Roundup: August 18-22

 in Los Angeles, California, Pearl Grimes, MD, moderated a presentation of 3 complex vitiligo cases to a full room of dermatology clinicians. Throughout the event, attendees discussed challenging patient histories, available treatments, and data on emerging options. Grimes, the director of the Vitiligo and Pigmentation Institute of Southern California, provided her expert commentary and experience for each case to further the conversation among peers.  

“I started the discussion by defining vitiligo as the trifecta of genetics, oxidative stress, and autoimmunity, and I told the attendees that the tenets of treatment are stabilization, repigmentation, and then being able to maintain repigmentation long term,” Grimes said.

In this case discussion, Grimes presented a 25-year-old Black man with vitiligo initially stable but later progressing to involve the cheeks, hands, and forearms. While the full extent of the disease was discussed, the focus shifted to limited facial involvement and its psychosocial impact. Grimes emphasized the significant burden vitiligo places on patients and reviewed findings from a large global study in 

 of over 2000 patients that characterized the wide-ranging psychosocial and quality-of-life effects of vitiligo.

 She also addressed the spectrum of patient acceptance and the clinician's role in validating patient concerns and aesthetic goals.

From a clinical management perspective, Grimes identified topical ruxolitinib as an appropriate first-line therapy for this patient, citing its efficacy and safety demonstrated in the 

 She noted that while some insurers require step therapy, proactive navigation of prior authorization processes can secure access. Grimes also discussed her laboratory monitoring approach, which is generally conducted annually or biennially, and tailored to patients’ needs. According to Grimes, this case demonstrates the importance of timely treatment, individualized care plans, and addressing access barriers to newer therapies such as topical JAK inhibitors.

In the second case discussion, Grimes presented a 33-year-old White woman with approximately 8% body surface area involvement and signs of rapidly progressive vitiligo. The patient had limited prior use of topical corticosteroids and was continuing to develop new lesions. Grimes discussed the critical need to halt disease progression, recommending a 6-week course of oral dexamethasone to achieve disease stabilization. However, she noted that some clinicians may extend treatment to 12 weeks. In the roundtable discussion, topical corticosteroids remained an option for localized areas.

According to Grimes, this case emphasized the pivotal role of narrowband UVB (NB-UVB) phototherapy in patients with extensive or progressive vitiligo. Grimes strongly supported combination therapy, citing clinical data showing superior outcomes with NB-UVB plus topicals compared to monotherapy. She also referenced 

 supporting the use of ruxolitinib in combination with NB-UVB, though she noted long-term efficacy and safety data are still pending.

In the final case, Grimes discussed a 13-year-old girl with vitiligo affecting the face and hands, present for one year with no family history. The patient had tried several topicals, including triamcinolone (discontinued due to lack of efficacy) and tacrolimus (discontinued due to burning and stinging), leading to increased frustration. Grimes highlighted the importance of a tailored, empathetic approach in pediatric vitiligo, noting that children and adolescents often respond better to treatment than adults but also face heightened psychosocial burden, especially related to bullying, social stigma, and self-esteem challenges during adolescence.

While discussing the psychosocial burden of vitiligo on younger patients, Grimes highlighted 

, an event hosted by the Global Vitiligo Foundation to support children with vitiligo and their families. This year’s event was held in Tampa, Florida, in June.

“Camp Victory was a phenomenal experience for me. This year, we had 40 kids, 40 parents, and 11 therapists from around the world. We had kids from Mexico, the UK, Canada, plus our contingency of kids from the US,” Grimes said.

She also emphasized shared decision-making, stating that visible areas should be treated if the child is motivated, and that pushing treatment on a reluctant teen may cause more harm than good. Ruxolitinib cream was identified as an appropriate and effective choice in this case, supported by post hoc analysis from TRuE-V1 data showing a higher likelihood of complete repigmentation in pediatric patients. Grimes also reviewed long-term efficacy data, pointing out that treatment response can continue to improve beyond 52 weeks, with peak repigmentation often occurring after 104 weeks.

“I envision a time with all of the interest in vitiligo. So, to come to 2025 and look back on the transformation from 2010 and 2012 through 2025, it brings me joy. It brings me pleasure. It brings me happiness for a segment of the medical community that was, I'm going to say, invisible,” Grimes concluded.

Bibeau K, Ezzedine K, Harris JE, et al. Mental health and psychosocial quality-of-life burden among patients with vitiligo: findings from the global VALIANT study. 

. 2023 Oct 1;159(10):1124-1128. doi: 10.1001/jamadermatol.2023.2787

Rosmarin D, Passeron T, Pandya AG, et al.TRuE-V study group. two phase 3, randomized, controlled trials of ruxolitinib cream for vitiligo. 

. 2022 Oct 20;387(16):1445-1455.doi: 10.1056/NEJMoa2118828

A study to evaluate the safety and efficacy of ruxolitinib cream with phototherapy in participants with vitiligo. Clinicaltrials.gov. Updated February 20, 2025. Accessed July 23, 2025. 

https://clinicaltrials.gov/study/NCT05247489

Camp Victory. Global Vitiligo Foundation. Accessed July 23, 2025. 

https://globalvitiligofoundation.org/camp-victory/

Wolkerstorfer A, Gooderham M, Sebastian M, et al. Efficacy of prolonged ruxolitinib cream treatment for vitiligo among patients with limited or no initial response at 6 months. Oral presentation at the 32nd EADV Annual Congress; October 11-14, 2023. Berlin, Germany.

The recent Dermatology Times Case-Based Roundtable event in Los Angeles, moderated by Dr. Pearl Grimes, focused on three complex vitiligo cases. The discussions highlighted the genetic, oxidative stress, and autoimmune components of vitiligo, emphasizing stabilization, repigmentation, and maintenance. Key treatments discussed included topical ruxolitinib, oral dexamethasone, and narrowband UVB phototherapy. The psychosocial impact of vitiligo, especially in pediatric patients, was underscored, with shared decision-making and patient motivation being crucial. The event also highlighted the importance of access to newer therapies and the evolving landscape of vitiligo treatment.

At a Dermatology Times Case-Based Roundtable event, Pearl Grimes, MD, led discussions on diverse vitiligo cases spanning adult, pediatric, and rapidly progressive disease, emphasizing individualized treatment strategies.

Jerome Okudo, MD, MPH

Articles

Latest Updated Articles